<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Harrington, Robert A.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Clinical Effectiveness for Cangrelor in PCI Not Persuasive</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">12-13</style></pages><abstract><style  face="normal" font="default" size="100%">The final results of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition [CHAMPION] PCI [NCT00305162] and CHAMPION PLATFORM [NCT00385138] trials showed no clinical benefit with cangrelor for the primary composite outcome of death, myocardial infarction, and ischemic-driven revascularization in patients who were undergoing percutaneous coronary intervention.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>